|
| |
TTP LabTech successfully deliver a fully automated chemistry
system for salt and polymorph screening to AstraZeneca
January 26th 2009 Royston, UK - TTP LabTech announced today that it had
successfully completed a major laboratory automation project with AstraZeneca.
The project, which took over three years to complete, involved the design and
build of a fully automated system for salt and polymorph screening of novel
compounds. The system completed its site acceptance test (SAT) late last year
before coming on-line at AstraZeneca’s research facility in Södertälje.
This unique system for synthesising and analysing crystalline materials was
designed in partnership between AstraZeneca and TTP LabTech. The overall
objectives were to increase throughput, to explore experimental space
efficiently and reliably and to automate the analysis of huge amounts of data.
The project has been undertaken in stages, the first of which was a prototyping
stage. This stage helped to minimise risk by tackling those design elements that
carried the greatest number of unknowns early in the project. The next stage was
the full design and build of a single screening machine to demonstrate control,
functionality, and consistency of the basic automated polymorph screening
processes. Now TTP LabTech has been asked to replicate the entire system in
order to double the overall throughput.
Dr Philip Blenkinsop, MD TTP LabTech commented: ‘This has been a very
challenging project for TTP LabTech requiring a number of novel solutions to be
developed from both a hardware and software perspective. The completion of the
first system is a real milestone and we look forward to delivering the next
system within the next year.’
The AstraZeneca Project Manager, Matti Ahlqvist commented, ‘Working in
partnership with TTP LabTech has resulted in an excellent solution. We set a
very demanding specification and are delighted that virtually all the
functionality has been achieved. Now that the first system is up and running for
our drug projects, we look forward to delivery of the second system and further
increasing throughput.’
Editors’ notes
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research,
development, manufacturing and marketing of prescription pharmaceuticals and
supplier for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US $29.55 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infection product sales. AstraZeneca is listed in the Dow Jones
Sustainability Index (Global) as well as the FTSE4Good Index
For more information visit:
www.astrazeneca.com
About TTP LabTech Ltd
Based near Cambridge, UK, TTP LabTech Ltd is a leading provider of development
services to the international life science community. TTP LabTech’s development
teams combine skills in chemistry, biology, and engineering to provide systems,
products, and processes which are both innovative and practical. With offices in
the UK, North America, and China the company is able to manage and support
custom development projects for client companies in virtually all parts of the
world.
For more information visit:
www.ttplabtech.com/custom-solutions/index.html
---ENDS---
Enquiries
TTP LabTech Limited
Jason Mundin +44 (0)1763 262626 Email:
jason.mundin@ttplabtech.com
AstraZeneca
Thomas Sueta +1 (302) 8858446 Email:
thomas.sueta@az.com
Media enquiries
Alto Marketing Limited
Clare Russell +44 (0)1489 557672 Email:
clarer@alto-marketing.com
| |
|
